N-phenyl-2-nitroacetamide | 10151-95-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-phenyl-2-nitroacetamide
• 英文别名: 2-nitro-N-phenylacetamide；2-nitro-1-phenylethan-1-one；2-nitroacetanilide；N-phenylnitroacetamide；Nitro-essigsaeure-anilid；nitroacetanilide；Nitroacetanilid
• CAS: 10151-95-8
• 化学式: C₈H₈N₂O₃
• 分子量: 180.163
• InChiKey: JFPJVTNYCURRAB-UHFFFAOYSA-N

物化性质

• 熔点：
  94°C
• 沸点：
  312.97°C (rough estimate)
• 密度：
  1.4190

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-phenyl-2-nitroacetamide 在 三氟甲磺酸 作用下， 以89%的产率得到(E)-1H-indole-2,3-dione 3-oxime
  参考文献：
  名称：

  Synthesis of Isatin 3-Oximes from 2-Nitroacetanilides

  摘要：

  通过碱性水解 1-芳基氨基-1-甲硫基-2-硝基乙烯制备的 2-硝基乙酰苯胺，在室温下用浓硫酸或三氟甲磺酸处理后可转化为异汀（1H-吲哚-2,3-二酮）3-肟。

  DOI：

  10.1055/s-1992-26223
• 作为产物：
  描述：

  N-二苯尿烷 在 phosphorus pentoxide 、 苯 作用下， 170.0 ℃ 、13.33 kPa 条件下， 生成 N-phenyl-2-nitroacetamide
  参考文献：
  名称：

  Michael, Chemische Berichte, 1905, vol. 38, p. 33

  摘要：

  DOI：

文献信息

• Stereoselective control in the Staudinger reactions involving monosubstituted ketenes with electron acceptor substituents: experimental investigation and theoretical rationalization
  作者：Hengzhen Qi、Xinyao Li、Jiaxi Xu

  DOI：10.1039/c0ob00783h

  日期：——

  The stereoselectivity of the Staudinger reactions involving monosubstituted ketenes with electron acceptor substituents was investigated experimentally by determination of the product stereochemistry and theoretically via DFT calculations. The results indicate that imines preferentially attack the less sterically hindered exo-side of the ketenes to generate zwitterionic intermediates. Subsequently, for cyclic imines, the intermediates undergo a conrotatory ring closure directly to produce β-lactams, while for linear imines, the imine moiety of the intermediates isomerizes to more stable intermediates, which further undergo a conrotatory ring closure to afford trans-β-lactams. The steric hindrance and the isomerization, rather than the torquoelectronic effect, play crucial roles in controlling the stereoselectivity in the practical Staudinger reactions involving monosubstituted ketenes with electron acceptor substituents, although the unaccessible borylketene with a powerful electron acceptor group controls the stereoselectivity torquoelectronically, in theory.

  通过确定产物立体化学和基于密度泛函理论（DFT）的计算，实验上研究了涉及带有电子受体取代基的单取代乙烯酮的斯陶丁格反应的立体选择性。结果表明，亚胺优先攻击乙烯酮上立体障碍较小的外侧，生成内鎓离子中间体。随后，对于环状亚胺，中间体直接进行协同环合反应生成β-内酰胺；而对于线性亚胺，中间体的亚胺部分异构化为更稳定的中间体，后者进一步进行协同环合反应，产生反式β-内酰胺。在实际涉及带有电子受体取代基的单取代乙烯酮的斯陶丁格反应中，立体障碍和异构化而不是扭曲电子效应在控制立体选择性中起着关键作用，尽管在理论上，具有强电子受体基团的不可获得的硼乙烯酮通过扭曲电子效应控制立体选择性。
• Dihydro-benzo[b][1,4]diazepin-2-one derivatives
  申请人：——

  公开号：US20030166639A1

  公开（公告）日：2003-09-04

  This invention relates to dihydro-benzo[b][1,4]diazepin-2-one derivatives of the formula 1 wherein R 1 , R 2 , X and Y are as defined in the specification and R 3 is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.

  这项发明涉及公式为1的二氢苯并[b][1,4]二氮杂二氢吡嗪-2-酮衍生物，其中R 1 ，R 2 ，X和Y如规范中所定义，R 3 是含有1至3个氮原子的六元芳香杂环或如规范中进一步定义的吡啶-N-氧化物。该发明还涉及含有这些化合物的药物、它们的制备方法以及它们用于制备治疗或预防急性和/或慢性神经系统疾病的药物。
• Dihydro-benzo [b][1,4]diazepin-2-one derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US06544985B2

  公开（公告）日：2003-04-08

  This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula wherein R1, R2, R3, X and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation, their use in preparation of pharmaceutical compositions and administration of an effective amount of the compounds for the treatment or prevention of acute and/or chronic neurological disorders to a patient in need of such treatment.

  这项发明是一种具有以下结构的二氢苯并[b][1,4]二氮杂环己酮衍生物的公式 其中R1、R2、R3、X和Y如规范中定义。该发明包括含有这些化合物的药物组合物，其制备方法，它们在制备药物组合物和向需要此类治疗的患者施用有效量的化合物以治疗或预防急性和/或慢性神经系统疾病的用途。
• Heterocyclic compounds
  申请人：ZENECA LIMITED

  公开号：EP0355049A2

  公开（公告）日：1990-02-21

  A herbicidal compound of formula (I): in which R' is independently selected from H, CN, N02, halogen, lower alkyl, lower haloalkyl; m is an integer of from 1 to 4; R2 is N or CR' where R1 is as defined above; R3 is a group of formula (a), (b) or (c): or N-oxide or quaternary salt derivatives thereof wherein R4 is a specified organic group. Processes for the preparation of these compounds and compositions containing them are also described.

  公式（I）的除草化合物：其中R'独立地选自H、CN、N02、卤素、较低的烷基、较低的卤代烷基；m是1到4的整数；R2是N或CR'，其中R1如上所定义；R3是公式（a）、（b）或（c）的基团：或其N-氧化物或季铵盐衍生物，其中R4是指定的有机基团。还描述了制备这些化合物和含有它们的组合物的方法。
• Inhibitors of human phosphatidylinositol 3-kinase delta
  申请人：——

  公开号：US20020161014A1

  公开（公告）日：2002-10-31

  Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&dgr;) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K&dgr; plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K&dgr;, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K&dgr; activity, including compounds that selectively inhibit PI3K&dgr; activity. Methods of using PI3K&dgr; inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K&dgr; inhibitory compounds to inhibit PI3K&dgr;-mediated processes in vitro and in vivo.

  揭示了抑制磷脂酰肌醇3-激酶δ异构体（PI3Kδ）活性的方法，以及治疗疾病的方法，例如免疫和炎症紊乱，其中PI3Kδ在白细胞功能中发挥作用。最好的方法是使用能够选择性抑制PI3Kδ的活性的活性剂，同时不显著抑制其他PI3K异构体的活性。提供了抑制PI3Kδ活性的化合物，包括选择性抑制PI3Kδ活性的化合物。还提供了使用PI3Kδ抑制性化合物抑制癌细胞生长或增殖的方法。因此，该发明提供了使用PI3Kδ抑制性化合物在体外和体内抑制PI3Kδ介导的过程的方法。